美國Repligen Corporation www.repligen.com
Repligen公司成立于1981年在特拉華州和在納斯達(dá)克上市，交易代碼RGEN。該公司的重點(diǎn)是對神經(jīng)系統(tǒng)疾病的新療法。發(fā)展計(jì)劃，目前正在對胰腺進(jìn)行磁共振成像等領(lǐng)域，躁郁癥，弗里德的共濟(jì)失調(diào)和脊髓性肌萎縮。此外，Repligen是世界上重組蛋白A的領(lǐng)先供應(yīng)商的利潤來自這有助于支持我們的臨床開發(fā)項(xiàng)目。

Repligen Corporation was incorporated in 1981 in Delaware and is traded on the NASDAQ under the symbol RGEN. The Company is focused on the development of novel therapeutics for neurological disorders. Development programs are currently being conducted in the areas of pancreatic MRI imaging, bipolar disorder, Friedreich's ataxia and spinal muscular atrophy. In addition, Repligen is the world's leading supplier of recombinant Protein A, the profits from which help to support our clinical development programs. Repligen has also secured a source of revenue through the successful licensing of CTLA4-Ig, and receives royalties from Bristol-Myers Squibb based on their U.S. sales of Orencia® for rheumatoid arthritis. The Company is located in Waltham, Massachusetts and currently has approximately 70 employees. 

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. A number of drug development programs are currently being conducted to evaluate our drug candidates in diseases such as bipolar disorder and Friedreich's ataxia.
We currently market recombinant Protein A, which partially funds the advancement of our product development pipeline while supporting our financial stability. In addition, we secured a source of revenue through the successful licensing of our patent covering the use of CTLA4-Ig, and receive royalties from Bristol-Myers Squibb based on their U.S. sales of Orencia® for rheumatoid arthritis.